Grafico Azioni Venture Life (LSE:VLG)
1 Anno : Da Gen 2019 a Gen 2020
RNS Number : 3683T
Venture Life Group PLC
20 March 2019
20 March 2019
VENTURE LIFE GROUP PLC
("Venture Life" or the "Group")
Notice of Results Update
Venture Life Group plc (AIM: VLG), announces that the Company expects to announce its audited results for the year ended 31 December 2018 in early April or before. This minor delay to the original timetable is a result of the audit process taking slightly longer than planned, due principally to recent personnel changes in the Company's finance function and increased complexity arising from the implications of reporting standards, including IFRS 9 and 15. Further to the announcement on 29 January 2019, the Company continues to expect to report revenue of GBP18.7 million, a 16% increase over the prior year and for adjusted EBITDA to be at least in line with market expectations.
For further information, please contact:
Venture Life Group PLC 578004
Jerry Randall, Chief Executive Officer
Cenkos Securities Ltd (Nomad and Broker) 8900
Mark Connelly / Stephen Keys / Cameron MacRitchie
Russell Kerr / Michael Johnson (Sales)
Rebecca Sanders-Hewett / Hilary Buchanan / Helena +44(0)20 3405
Bogle / Jessica Joynson 0208
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
(END) Dow Jones Newswires
March 20, 2019 03:02 ET (07:02 GMT)